GSK plc (GSK.L) Tuesday said that the European Medicines Agency has accepted the Marketing Authorisation Application for depemokimab in two indications including asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
The submissions were based on data from SWIFT and ANCHOR studies. Results from the SWIFT-1 and -2 studies showed that depemokimab reduced exacerbation and hospitalisation rates when used as an add-on therapy for patients with asthma with type 2 inflammation. ANCHOR-1 and -2 trial showed depemokimab reduced nasal polyp size and obstruction compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.